2015
Nephrogenic Systemic Fibrosis
LaChance A, Abu-Alfa A, Cowper S. Nephrogenic Systemic Fibrosis. 2015, 119-136. DOI: 10.1007/978-1-4939-2395-3_12.ChaptersNephrogenic systemic fibrosisMagnetic resonance angiographySystemic fibrosisNon-renal patientsOff-label useDiverse medical specialtiesMedication toxicityRenal diseasePathological featuresRenal populationRare conditionUnsuspected conditionsLong-term effectsNew toxicitiesGadolinium retentionResonance angiographyDisease causesTreatment climateNovel diseaseMedical specialtiesFibrosisDiseasePhysiciansPharmaceutical companiesToxicity
2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilance
2013
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report
Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2013, 44: 173-180. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisGadolinium-based contrast agentsDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemEvent Reporting SystemRenal functionPediatric casesResearch RegistryContrast agentsFibrosisDuplicate reportingU.S. FoodSystematic searchReported numberRegistryChildrenReporting systemFAERSExposureReportAgentsMethodsWeCases
2011
Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations
Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiagnosis of NSFNephrogenic systemic fibrosisClinicopathological definitionNSF diagnosisWorkup recommendationsPrior clinical experienceClinicopathological presentationRenal diseaseHistopathological featuresRisk factorsStudy populationPrecise causationSystemic fibrosisClinical experienceAccurate diagnosisClinical expertiseDiagnostic standardHistopathological atlasDiagnosisGold standardMedical investigationsCompelling associationPhysiciansIndisputable linkContrast agentsNephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2010
Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDisease
2009
Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation
Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu‐Alfa A, Cowper SE, Bucala R, Gomer RH. Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging 2009, 30: 1284-1288. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNephrogenic systemic fibrosisSerum amyloid PFibrocyte differentiationDifferentiation of monocytesNSF patientsBlood mononuclear cellsHemodialysis patientsInterleukin-12Mononuclear cellsPurified monocytesFibroblast-like cellsFibrotic lesionsHealthy controlsSystemic fibrosisAmyloid PContrast agentsPatientsMonocytesDifferentiation inhibitorWiley-LissFibrocytesOmniscanDifferentiation protocolsCellsGadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned?
Weinreb JC, Abu‐Alfa A. Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? Journal Of Magnetic Resonance Imaging 2009, 30: 1236-1239. PMID: 19938035, DOI: 10.1002/jmri.21979.Commentaries, Editorials and LettersMRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction
Kuo P, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, Weinreb J, Cowper S. MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. Applied Radiology 2009, 22-33. DOI: 10.37549/ar1683.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNephrogenic systemic fibrosis
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosisThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio
2007
Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? American Journal Of Roentgenology 2007, 189: w169. PMID: 17715089, DOI: 10.2214/ajr.07.2252.Peer-Reviewed Original Research